Phase III clinical trial of ultra-course Rifapentine/Isoniazid for the prevention of active tuberculosis in HIV-infected individuals with latent tuberculosis infection

Project no.: A5279 (Short Course Treatment of Latent TB) (NCT01404312)

This study will compare rifapentine plus isoniazid daily for 4 weeks to a standard regimen of isoniazid alone daily for 9 months for the prevention of tuberculosis (TB) in HIV-infected participants who do not show evidence of active TB.